USFDA completes inspection at Aurobindo Pharma's Unit VII in Hyderabad

5 Aug 2022 , 12:23 PM

Aurobindo Pharma Ltd has informed to the exchanges regarding completion of USFDA Inspection at its registered Unit VII.

According to the filing, the Company’s Unit VII, an oral manufacturing facility situated at Jedcherla, Hyderabad, received an Establishment Inspection Report (EIR) mentioning the inspection a Voluntary Action Initiated (VAl) from the USFDA and with this inspection is concluded, the company said.

At around 12:22 PM, Aurobindo Pharma was trading at Rs572.90 per share up by Rs1.85 or 0.32% from its previous closing of Rs571.05 per share on the BSE.

The scrip opened at Rs571 and has touched a high and low of Rs587.05 and Rs570.60 respectively so far today. The current market cap of the company is Rs33,460.02 crore.